Defining parameters of specificity for bioluminescent optogenetic activation of neurons using in vitro multi electrode arrays (MEA)
| Autor: | Mansi Prakash, Ute Hochgeschwender, William E. Medendorp |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
0301 basic medicine Opsin genetic structures Primary Cell Culture Channelrhodopsin Optogenetics Article Membrane Potentials Rats Sprague-Dawley 03 medical and health sciences Cellular and Molecular Neuroscience chemistry.chemical_compound 0302 clinical medicine Coelenterazine Animals Bioluminescence Premovement neuronal activity Luciferase Luciferases Neurons Opsins Chemistry Luciferin Electrodes Implanted Luminescent Proteins 030104 developmental biology Luminescent Measurements Biophysics Female sense organs 030217 neurology & neurosurgery |
| Zdroj: | Journal of Neuroscience Research. 98:437-447 |
| ISSN: | 1097-4547 0360-4012 |
| Popis: | In Bioluminescent Optogenetics (BL-OG) a biological, rather than a physical, light source is used to activate light-sensing opsins, such as channelrhodopsins or pumps. This is commonly achieved by utilizing a luminopsin (LMO), a fusion protein of a light emitting luciferase tethered to a light-sensing opsin. Light of the wavelength matching the activation peak of the opsin is emitted by the luciferase upon application of its small molecule luciferin, resulting in activation of the fused opsin and subsequent effects on membrane potential. Using optimized protocols for culturing, transforming, and testing primary neurons in multi electrode arrays, we systematically defined parameters under which changes in neuronal activity are specific to bioluminescent activation of opsins, rather than due to off-target effects of either the luciferin or its solvent on neurons directly, or on opsins directly. We further tested if there is a direct effect of bioluminescence on neurons. Critical for assuring specific BL-OG effects are testing the concentration and formulation of the luciferin against proper controls, including testing effects of vehicle on LMO expressing and of luciferin on non-LMO expressing targets. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text